News

1. SMC Pharma Services Enters Autoinjector Development Agreement With A Biopharmaceutical Company For The Bios Platform 10/21/2024

   SMC Pharma Services has partnered with a biopharmaceutical company to develop an autoinjector platform solution for a rare disease clinical trial.

2. BD And ten23 health® Partner To Advance Efficiency And Quality In Aseptic Manufacturing With RFID-Enabled Prefillable Syringes 10/8/2024

   BD (Becton, Dickinson and Company) and ten23 health announced a collaboration to develop a new way to track refillable syringes using RFID technology.

3. WuXi STA Debuts Its First High Potency Sterile Injectable Manufacturing Line At Wuxi City Site 7/17/2023

   WuXi STA – a global Contract Research, Development, and Manufacturing Organization (CRDMO) – launches a first high potency (HP), fully automated sterile injectable manufacturing line at its drug product site in Wuxi City, China.

4. Innovative Drug Formulations Make Medicines More Patient-Friendly: Aenova And Galvita Enter Strategic Partnership 7/13/2023

   The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a full service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health.

5. Race Executes Agreement With Ardena For GMP Manufacturing Of RC220 7/12/2023

   Race Oncology Limited ("Race") is pleased to announce that it has signed an agreement with leading global contract development and manufacturing organisation (CDMO), Ardena Holding NV (Ardena) to provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race's flagship intravenous (IV) formulation of bisantrene, RC220.

6. Strategic Partnership For Dose Counter Technology Production 7/11/2023

   Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart, a market leader in respiratory drug delivery systems design, development, and manufacturing, are partnering with Chiesi Group, an international research-focused biopharmaceutical and healthcare group, for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. 

7. Acasti Announces WuXi Clinical As CRO To Conduct STRIVE-ON Pivotal Phase 3 Safety Trial For GTX-104 In aSAH Patients 7/10/2023

   Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104, today announced WuXi Clinical Development, Inc. ("WuXi Clinical"), a wholly owned subsidiary of WuXi AppTec, a global Contract Research Organization (CRO), will conduct Acasti's STRIVE-ON Phase 3 safety trial for GTX-104. GTX-104 is Acasti's novel, injectable nimodipine formulation for intravenous infusion (IV) that addresses high, unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH).

8. Meissa Vaccines Enters Into cGMP Manufacturing Agreement For Pediatric RSV Vaccine Candidate For Phase 2 Clinical Trials 6/28/2023

   Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced it has entered into a manufacturing agreement with Exothera S.A. (“Exothera”), a Univercells company and full-service Contract Research Development and Manufacturing Organization (CRDMO) delivering customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids.

9. Stevanato Group Presents Vertiva, A Versatile On-Body Delivery System Platform For A Wide Range Of Injectable Therapies And For Large Delivery Volumes (Up To 100mL) 6/12/2023

   Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled today Vertiva, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies.

10. Corning And SGD Pharma Announce Joint Venture To Open New Glass Tubing Facility And Expand Access To Corning Velocity Vial Technology In India 6/8/2023

    Corning Incorporated and SGD Pharma today announced a joint venture that includes the opening of a new glass tubing facility to expand pharmaceutical manufacturing in India and allows SGD Pharma to adopt Corning’s Velocity Vial technology platform.